<DOC>
	<DOCNO>NCT00297063</DOCNO>
	<brief_summary>This study design compare efficacy safety BRL49653C versus pioglitazone placebo .</brief_summary>
	<brief_title>BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus . Managed diet therapy . Must adequate blood , liver kidney function . Exclusion criterion : Serious cardiovascular disease serious hepatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>rosiglitazone</keyword>
	<keyword>vandia</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>diabetes ;</keyword>
</DOC>